For more than three decades, antidepressants like selective serotonin reuptake inhibitors (SSRIs) have been the primary pharmacological intervention for people with depression. These drugs are based on the monoamine hypothesis, which posits that a deficiency of monoamine neurotransmitters, including serotonin, dopamine, and norepinephrine, are — at least in part — the cause of depression. But these drugs are not without downsides. They often take weeks to work, they don’t work for everyone, and the side effects can sometimes be too much. Scientists in China believe they have made progress toward solving at least some of those antidepressant downsides. In a...